Journal: Bioorganic Chemistry

Article Title: Novel hit of DPP-4Is as promising antihyperglycemic agents with dual antioxidant/anti-inflammatory effects for type 2 diabetes with/without COVID-19

doi: 10.1016/j.bioorg.2022.106092

Figure Lengend Snippet: Schematic representation for DPP-4/Substrate complex.

Article Snippet: The active compounds in SLM were screened for their DPP-4 inhibition activities as previously described , using Fluorogenic DPP-4 Assay Kit (Bps Bioscience Cornerstone Court W, Ste B San Diego, CA 92121) following the manufacturer’s instructions.

Techniques:

Journal: Bioorganic Chemistry

Article Title: Novel hit of DPP-4Is as promising antihyperglycemic agents with dual antioxidant/anti-inflammatory effects for type 2 diabetes with/without COVID-19

doi: 10.1016/j.bioorg.2022.106092

Figure Lengend Snippet: Naturally occurring phenolic compounds having DPP-4 inhibition potent activity.

Article Snippet: The active compounds in SLM were screened for their DPP-4 inhibition activities as previously described , using Fluorogenic DPP-4 Assay Kit (Bps Bioscience Cornerstone Court W, Ste B San Diego, CA 92121) following the manufacturer’s instructions.

Techniques: Inhibition, Activity Assay

Journal: Bioorganic Chemistry

Article Title: Novel hit of DPP-4Is as promising antihyperglycemic agents with dual antioxidant/anti-inflammatory effects for type 2 diabetes with/without COVID-19

doi: 10.1016/j.bioorg.2022.106092

Figure Lengend Snippet: In vivo DPP-4 activity as % of control in type2 diabetic rats, Values are mean ± SD (n = 3). ***significant (P < 0.001) compared to control diabetic group.

Article Snippet: The active compounds in SLM were screened for their DPP-4 inhibition activities as previously described , using Fluorogenic DPP-4 Assay Kit (Bps Bioscience Cornerstone Court W, Ste B San Diego, CA 92121) following the manufacturer’s instructions.

Techniques: In Vivo, Activity Assay

Journal: Bioorganic Chemistry

Article Title: Novel hit of DPP-4Is as promising antihyperglycemic agents with dual antioxidant/anti-inflammatory effects for type 2 diabetes with/without COVID-19

doi: 10.1016/j.bioorg.2022.106092

Figure Lengend Snippet: 2D binding modes of compounds (4b, 4c, 6a, 6b, 7d, 8b) and Linagliptin with DPP-4 active site.

Article Snippet: The active compounds in SLM were screened for their DPP-4 inhibition activities as previously described , using Fluorogenic DPP-4 Assay Kit (Bps Bioscience Cornerstone Court W, Ste B San Diego, CA 92121) following the manufacturer’s instructions.

Techniques: Binding Assay

Journal: Bioorganic Chemistry

Article Title: Novel hit of DPP-4Is as promising antihyperglycemic agents with dual antioxidant/anti-inflammatory effects for type 2 diabetes with/without COVID-19

doi: 10.1016/j.bioorg.2022.106092

Figure Lengend Snippet: 3D binding mode of compound 6a with DPP-4 active site.

Article Snippet: The active compounds in SLM were screened for their DPP-4 inhibition activities as previously described , using Fluorogenic DPP-4 Assay Kit (Bps Bioscience Cornerstone Court W, Ste B San Diego, CA 92121) following the manufacturer’s instructions.

Techniques: Binding Assay

Journal: British Journal of Cancer

Article Title: PARP inhibitor-induced anti-tumour chemokine response is suppressed by dipeptidyl peptidase 4 (DPP4) in ovarian cancer

doi: 10.1038/s41416-025-03076-4

Figure Lengend Snippet: a Animal experiment designed to investigate the effect of the combination treatment of olaparib with sitagliptin, placebo and sitagliptin groups pooled from two separate experiments. b DPP4 activity assay with tumour homogenates collected at the time of animal sacrifice from the animal experiment displayed in ( a ) without pooled placebo and sitagliptin groups, significant differences were determined by one-way ANOVA with Tukey’s multiple comparisons test. c ELISA-quantification of mCCL5 or mCXCL10, respectively, from the animal experiment displayed in ( a ), displayed relative to placebo, pooled from two individual experiments and normalised to the mCCL5 or mCXCL10 means in the corresponding placebo group, significant differences were determined by one-way ANOVA with correction for multiple comparisons (Dunnett). d Kaplan-Meier plot showing survival of C57BL/6 mice from the animal experiment displayed in ( a ). The statistical significance of Kaplan-Meier analyses was calculated using the Log-rank test or the Gehan-Breslow-Wilcoxon test when groups crossed each other. ELISA results represent the mean, error bars are SEM, n.s. = not significant, alpha = 0.05.

Article Snippet: The mouse DPP4 construct BC022183 was excised from a DPP4 -containing vector ( DPP4 ( BC022183 ) Mouse Untagged Clone, MC200935 , OriGene) and ligated into the transfer vector pSMPUW-Neo.

Techniques: Activity Assay, Enzyme-linked Immunosorbent Assay

Journal: British Journal of Cancer

Article Title: PARP inhibitor-induced anti-tumour chemokine response is suppressed by dipeptidyl peptidase 4 (DPP4) in ovarian cancer

doi: 10.1038/s41416-025-03076-4

Figure Lengend Snippet: a IHC hDPP4 staining was performed with tissue microarray samples from 208 patients with HGSOC. Depicted images were used as reference images to evaluate the hDPP4 staining. b Pie chart showing the distribution of staining intensities from ( a ). c Activity assay displaying DPP4 activity in fresh-frozen tumour samples from patients of the cohort from ( a ) ( n = 33), categorised into the staining groups determined in ( b ) score 0 ( n = 13), score 1 ( n = 4), score 2 ( n = 7), and score 3 ( n = 9), three outliers were excluded by the ROUT method with Q = 1%. d Kaplan-Meier analysis of patient overall survival stratified into the hDPP4 low expressing group (score 0-2 from ( b ), n = 196) and the hDPP4 high expressing group (score 3 from ( b ), n = 12). e Kaplan-Meier plot showing survival of C57BL/6 mice intraperitoneally inoculated with syngeneic ID8-Trp53 (−/−) mDPP4 + ( n = 14) or ID8-Trp53 (−/−) empty ( n = 14) pooled from three individual experiments. f Kaplan-Meier plot showing survival of C57BL/6 mice intraperitoneally inoculated with syngeneic ID8-Trp53 (−/−) Brca2 (−/−) mDPP4 + ( n = 8) or ID8-Trp53 (−/−) Brca2 (−/−) empty ( n = 8). g KM-plotter survival analysis with the following parameters: use multiple genes, Filter by median expression, Gene symbol: 203717_at (DPP4), include only patients with high expression of gene 214727_at (BRCA2), start analysis using selected genes, auto select best cutoff, OS, Histology: serous, Stage: 3 + 4, Grade: 3, TP53 mutation: mutated, Debulk: optimal. h KM-plotter survival analysis like ( g ) but with the following parameter change: include only patients with low expression of gene 214727_at (BRCA2). Statistical significance of Kaplan-Meier analyses was calculated using Log-rank test or, when groups crossed each other, Gehan-Breslow-Wilcoxon test. Activity assay results represent the mean, error bars are SEM, significant differences were determined by Welch’s ANOVA with Tamhane’s T2 multiple comparisons test.

Article Snippet: The mouse DPP4 construct BC022183 was excised from a DPP4 -containing vector ( DPP4 ( BC022183 ) Mouse Untagged Clone, MC200935 , OriGene) and ligated into the transfer vector pSMPUW-Neo.

Techniques: Staining, Microarray, Activity Assay, Expressing, Mutagenesis